Search

Displaying results 8441 - 8450 of 10000 in total
  1. Drug

    Rufloxacin

    go.drugbank.com/drugs/DB13772
    Investigational

    Rufloxacin is a quinolone antibiotic.[A31894]

  2. Drug

    Linopirdine

    go.drugbank.com/drugs/DB13806
    Experimental

    Categories: Compounds used in a research, industrial, or household setting
  3. Drug

    Cyfluthrin

    go.drugbank.com/drugs/DB13828
    Experimental

    Categories: Compounds used in a research, industrial, or household setting
  4. Drug

    Potassium permanganate

    go.drugbank.com/drugs/DB13831
    Investigational

    Categories: Compounds used in a research, industrial, or household setting
  5. Drug

    Fosfructose

    go.drugbank.com/drugs/DB13863
    Investigational

    Categories: Compounds used in a research, industrial, or household setting
  6. Drug

    Equine Botulinum Neurotoxin E Immune FAB2

    go.drugbank.com/drugs/DB13897
    Approved

    Equine Botulinum Neurotoxin E Immune FAB2 is composed of a mixture of immune globulin fragments purified from plasma of horses that were previously immunized with botulinum toxin serotype E.

  7. Drug

    Equine Botulinum Neurotoxin C Immune FAB2

    go.drugbank.com/drugs/DB13898
    Approved

    Equine Botulinum Neurotoxin C Immune FAB2 is composed of a mixture of immune globulin fragments purified from plasma of horses that were previously immunized with botulinum toxin serotype C.

  8. Drug

    Equine Botulinum Neurotoxin B Immune FAB2

    go.drugbank.com/drugs/DB13903
    Approved

    Equine Botulinum Neurotoxin B Immune FAB2 is composed of a mixture of immune globulin fragments purified from plasma of horses that were previously immunized with botulinum toxin serotype B.

  9. Drug

    2'-C-methylcytidine

    go.drugbank.com/drugs/DB13921
    Experimental

    A nucleoside analog with anti-hepatitis C virus (HCV) activity.

  10. Drug

    Ulixertinib

    go.drugbank.com/drugs/DB13930
    Investigational

    Ulixertinib is a a novel, reversible, ATP-competitive ERK1/2 inhibitor with high potency and ERK1/2 selectivity [A31474]. … It is currently in clinical trials for the treatment of a wide range of tumors.